Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001831942-25-000029
Filing Date
2025-11-14
Accepted
2025-11-14 16:57:49
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10402
2 exhibit1jointfilingagreement.htm EX-1 3374
  Complete submission text file 0001831942-25-000029.txt   15777
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Subject) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90431 | Film No.: 251487832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022 212-256-8600
Commodore Capital LP (Filed by) CIK: 0001831942 (see all company filings)

EIN.: 832659606 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A